Introduction: Two Breakthrough Updates in Chemical Reprogramming

• Two recent scientific advances suggest that biological age could be reversed with simple molecules instead of complex gene therapies.
• Dr. David Sinclair's lab presented preliminary data on SL100; Dr. Alejandro Ocampo published a study using a two-molecule cocktail.

Ocampo's Two-Molecule Formula: Tranylcypromine & Repsox

• Ocampo reduced an original seven-molecule mixture to only two compounds: Tranylcypromine (TCP) and Repsox.
• TCP inhibits LSD1, an enzyme that removes methyl groups from histones – this restores chromatin compaction and suppresses transposable elements.
• Repsox blocks the TGFβ receptor ALK5, reducing oxidative stress and inflammatory markers.

Results in Cell Cultures

• In dermal fibroblasts from older donors (56–83 years), treatment led to:
  • Normal cell division (unlike the seven-molecule mixture)
  • Reduced DNA double-strand breaks and senescence markers (p21, p53, IL-6)
  • Increased repressive chromatin marks (H3K9me3, H3K27me3), persisting 30 days after removal
• No collagen damage or fibrosis – cell identity was largely preserved.

Lifespan Extension in Nematodes (C. elegans)

• Continuous treatment increased median lifespan by 42.1% (from 19 to 27 days).
• Single compounds each gave 31.6% – the combination was slightly superadditive.
• Treated worms showed better movement, longer reproductive window, and increased resistance to oxidative stress.

Sinclair's SL100: Preliminary Mouse Data

• In rapidly aging 'LAKI' mice (progeria model), SL100 prevented weight loss.
• Median lifespan increased by 15.4% (not significant), maximum lifespan trended above 33%.
• SL100 is a proprietary oral candidate; results are still unpublished.

Pharmacological Challenges & Safety Concerns

• Tranylcypromine irreversibly inhibits monoamine oxidase (MAO) – interaction with tyramine-rich foods (cheese, red wine) can cause hypertensive crises.
• Repsox systemically blocks TGFβ – this can damage heart valves and blood vessels.
• Thus, these molecules are research tools, not immediately applicable therapeutics.

Outlook & Next Steps

• Ocampo's work shows that two molecular nodes suffice – this enables development of safer second-generation compounds.
• Gladyshev's study (2026) warned of lipid accumulation in liver and kidney in mice with seven-molecule mix – even the two-molecule combo induced lipid droplets in mouse cells.
• Translation to humans requires selective LSD1 inhibitors without MAO activity, and tissue-specific ALK5 inhibitors.

Conclusion

• Chemical reprogramming is a promising but still early field of research.
• Readers are invited to share their opinion: Local gene therapy vs. targeted small molecules.

Insider Selling in AI Stocks: A Warning Sign?

This video analyzes massive insider stock sales at leading AI companies since June 2025. It reveals a pattern that goes beyond routine financial planning.

Key Figures and Sales Volume

• Nvidia (Director Mark Stevens): Sold approximately $1.35 billion worth of stock on the open market (virtually all insider sales at the company).
• Broadcom (Chairman Henry Samueli): Two sales packages totaling around $500 million (each ~$250 million).
• Arista (CEO Jayshree Ullal): Sales of about $145 million, with $131 million occurring within four days in October.
• CoreWeave (CSO Brian Venturo): Since the IPO, sales exceeding $1.2 billion, primarily after the lock-up period expired.

Why Are They Selling?

• Planned Sales (10b5-1 Plans): Most sales occur through pre-arranged trading plans, protecting insiders from insider trading accusations. The decision to sell is often made months in advance.
• Timing of Sales: Many sales happen right after quarterly earnings reports or during price strength.
• Lack of Purchases: The key signal: At Nvidia, Arista, and CoreWeave, there has been not a single insider purchase on the open market in the last 12 months. At Broadcom, one small purchase was dwarfed by $500 million in sales.

Conclusion

The video presents two interpretations:

1. Bearish View: Insiders are cashing out near the peak of the AI hype, believing valuations are unsustainable.
2. Neutral View: This is routine portfolio diversification, tax planning, and estate management, planned long in advance.

Key Takeaway: The absence of insider purchases combined with massive selling is a noteworthy indicator that warrants attention.

Introduction: Payment for Orderflow Ban

• Since July 2026, brokers are no longer allowed to accept fees for forwarding orders to specific exchanges. This Payment for Orderflow Ban was feared to increase costs, but surprisingly some areas have even become cheaper.

Depot Fees and Basics

• Out of 56 tested brokers, 31 offer a completely free depot with no conditions.
• Comdirect has peculiar terms: new customers get it free, but existing customers pay €1.95/month.
• Overall, 11 depots receive the top rating, all with free ETF savings plans.

ETF Savings Plans and Details

• Only 22 depots fulfill both basic conditions (free depot + free ETF savings plans).
• Smart Broker Plus, ING, and Consorsbank currently offer free plans, but without permanent guarantee.
• New filter: Search for your specific ETF and check if it can be invested in for free.
• Execution days vary: Trading 212 offers flexible dates, Scalable Capital has 9 dates.

Order Fees and Taxes

• Orders: Trading 212 is completely free; Neobrokers often free from €500 or charge €1.
• Traditional banks (ING, Consorsbank) charge percentage fees (e.g., 1.75% at ING).
• Xetra trading is becoming cheaper (Trade Republic €2, Scalable €1.99).
• Taxes: All Top11 automatically handle capital gains tax. Beware of Revolut, XTB, eToro – you must handle taxes yourself.

Interest on the Cash Account

• Trading 212 promotes 4.2% promotional interest (new customers, 4 months), then 2.8%. However, partly invested in money market funds.
• Trade Republic offers 2.5%, Scalable Capital 2.6% (on a separate savings account).
• Interest often needs to be activated.

Test Winner and Alternatives

• 1st place: Traders Place – low fees, sub-accounts for FIFO trick, €60 bonus via Finanzfluss.
• 2nd place: Scalable Capital, 3rd place: Trading 212 – own depot management, solid conditions.

App Overview

• Quick look at the apps of Traders Place, Scalable Capital, and Trading 212: portfolio overview, savings plan setup, cash accounts.

Conclusion

Despite the Payment for Orderflow Ban, the market remains competitive. Choosing the right depot depends on individual behavior – the Finanzfluss depot comparison helps with the decision.

Bitcoin and the Spooky Market Situation at Halloween 🎃

The speaker analyzes a potential four-year cycle low for Bitcoin and highlights current, disturbing („spooky“) chart patterns.

• Current Status: Bitcoin is around 77,000–78,000 $ and has reached the bull market support band.
• Historical Parallels: False breakouts also occurred in 2015, 2019-2020, and 2022. These phases often ended with sharp declines (capitulation).
• Apathetic Top: The current breakout resembles 2019-2020 (an apathetic high), which is more prone to false signals than euphoric highs.

Macroeconomic and Cross-Market Signals 📉

Several external factors point to further pullbacks:

• Interest Rate Hikes: A rate hike in September of a midterm election year historically led to lows about 40 days later – right in the current time window.
• Stock Markets: The NASDAQ has already fallen over 10%. The S&P 500, Gold, and the South Korean market show similar patterns (Q1 low, Summer low, Q4 low).
• IPOs: Liquidity is draining from Bitcoin ahead of the Anthropic IPO (mid-November), similar to the SpaceX IPO before.

Potential Lows and the „Balance Price“ 💰

Technical analysis points to specific price targets:

• Realized Price: In every bear market, Bitcoin fell below this level. This could happen again.
• Balance Price: This lies around 38,000 $. All previous bear markets ended at this line.
• Bitcoin vs. Gold: The ratio could fall to 10. With gold at 3,800 $, this would mean a Bitcoin price of 40,000 $.
• Cycle Low: The speaker expects a Q4 low and advises respecting the market, not one's own wishes. A drop of 20% to the lower range ends is possible – meaning prices around 60,000 $.

Summary of the Spooky Scenarios 👻

• Call for Caution: The speaker warns against recklessness, even if the market shows short-term recoveries.
• Most Bullish Case: Bitcoin finds a higher low and starts a new rally.
• Most Bearish Case (Tail Risk): Bitcoin falls to the Balance Price (38,000–40,000 $) before the bear market ends.
• Actionable Advice: The market should be traded on its own terms. The burden of proof currently lies with the bulls.

The speaker reminds viewers of the upcoming ITC conference and asks for subscriptions and likes.

Core Message

The guest explains why the current hype around tokenization and real-world assets on blockchains could be a bullish signal for Bitcoin – even though it seems counterintuitive.

Historical Context

• Before 2017 (e.g., 2014–2016), there were phases where traditional financial institutions emphasized blockchain but dismissed Bitcoin ("blockchain, not Bitcoin").
• These so-called "permissioned blockchains" (e.g., R3 Corda, IBM Hyperledger, JP Morgan Quorum/Onyx) barely created real change, according to the guest.
• The pattern is repeating now: Many are talking about tokenization while Bitcoin and Ether are being written off.

Current Developments

• Unlike earlier, there is now real progress in institutional adoption of crypto assets and use of permissionless chains.
• Tokenization of real-world assets (e.g., money market funds) will happen and improve efficiency and transparency in traditional markets.
• There are already many panels and discussions on this topic (e.g., Korea Blockchain Week, Token2049).

Why This Is a Buy Signal

• Historically, whenever the "pendulum" swung strongly toward blockchain (instead of Bitcoin), it was a good time to buy Bitcoin.
• The guest emphasizes: Bitcoin addresses the core problem of trust in traditional currencies (according to Satoshi), while tokenization is only a technological revolution for efficiency.
• Both can happen in parallel, but Bitcoin remains the deeper revolution.

Conclusion

• The contrarian approach – being optimistic and going long when everyone else focuses elsewhere – is seen as promising.
• The coming years could show that the tokenization boom is indeed a precursor for a new Bitcoin rally.

• The Femobook A68 is a single-dose coffee grinder priced at approx. €800. Despite some positive online feedback, the testers reach a different conclusion.

Exterior & Technical Specs

• Conical 68 mm burrs, weight ~6 kg, aluminum body.
• Dimensions: 10 cm width, 16 cm depth (without plug), 30 cm height.
• 200 W DC motor running at 60–80 RPM.

Operation

• Positives: Very good adjustability and reproducibility – small click changes yield minimal extraction time variation (max 2 seconds). Tool-less disassembly for easy cleaning.
• Negatives: Without RDT (water spray), severe static issues and mess; coffee sticks everywhere; with RDT it’s acceptable. The dosing cup is slightly small.

Espresso Quality

• Taste: Lacks sweetness, body, and elegance – bitter, murky, dry. The testers call it one of the worst espressos they ever had.
• Extraction behavior: Initially fast flow, slowing down toward the end – indicating clogging due to fine particles.
• Particle distribution: Broad main peak (>320 µm) and high fines. This leads to uneven extraction (over-extraction of fines, under-extraction of coarse particles).

Filter Coffee

• Not tested, as the particle distribution would not produce good filter coffee.

Conclusion

• Despite decent usability and adjustability, the A68 lets down heavily in cup quality. It may be a unit-specific issue; the testers invite viewers to share their experiences in the comments.